Citations

Mayo Clinic

Showing 10 of 108602 citations.

SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Kottschade, Lisa A. , Pond, Gregory R. , Olszanski, Anthony J. , Zakharia, Yousef , Domingo‐Musibay, Evidio , Hauke, Ralph J. , Curti, Brendan D. , Schober, Sarah , Milhem, Mohammed , Block, Matthew S. , Pond, Gregory Russell , Milhem, Mohammed M , Block, Matthew S , Hieken, Tina J , McWilliams, Robert R , Olszanski, Anthony J , Zakharia, Yousef , Hieken, Tina J. , McWilliams, Robert R.

Clinical Cancer Research | March 31, 2023 | Volume: 29 | Issue: 12 | Pages: 2220-2225

10.1158/1078-0432.ccr-22-3207 | PMID 37000165 Get It

Abstract Purpose: Mucosal melanoma is a rare, aggressive form of melanoma with extremely high recurrence rates despite definitive surgical resection with curative intent. Currently there is no consensus on adjuvant therapy. Data on checkpoint inhibitors for adjuvant therapy are lacking. Patients and Methods: We performed a single-arm, multicenter clinical trial using “flip dose” ipilimumab (1 mg/kg q3w × 4 cycles), and nivolumab (3 mg/kg q3w × 4 cycles), then nivolumab 480 mg q4w × 11 cycles to complete a year of adjuvant therapy. Participants must have had R0/R1 resection ≤90 days before registration, no prior systemic therapy (adjuvant radiotherapy allowed), ECOG 0/1, and no uncontrolled autoimmune disease or other invasive cancer. Patients were recruited through the Midwest Melanoma Partnership/Hoosier Oncology Network. Results: From September 2017 to August 2021, 35 patients were enrolled. Of these, 29 (83%) had R0 resections, and 7 (20%) received adjuvant radiotherapy. Median age was 67 years, 21 (60.0%) female. Recurrence-free survival (RFS) rates at 1 and 2 years were 50% [95% confidence interval (CI), 31%–66%] and 37% (95% CI, 19%–55%), respectively. Overall survival rates at 1 and 2 years were 87% (95% CI, 68%–95%) and 68% (95% CI, 46%–83%), respectively. Median RFS was 10.3 months (95% CI, 5.7–25.8). Most common grade 3 toxicities were diarrhea (14%), hypertension (14%), and hyponatremia (11%), with no grade 4/5 toxicities. Conclusions: Flip-dose ipilimumab and nivolumab after resection of mucosal melanoma is associated with outcomes improved over that of surgical resection alone. Long-term follow-up, subgroup analyses and correlative studies are ongoing.
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Westin, Jason R. , Locke, Frederick L. , Dickinson, Michael , Ghobadi, Armin , Elsawy, Mahmoud , Meerten, Tom van , Miklos, David B. , Ulrickson, Matthew L. , Perales, Miguel‐Angel , Farooq, Umar , Leslie, Lori A. , Kersten, Marie José , Jacobson, Caron A. , Pagel, John M. , Wulf, Gerald , Johnston, Patrick B. , Rapoport, Aaron P. , Du, Linqiu , Vardhanabhuti, Saran , Filosto, Simone , Shah, Jina , Snider, Julia Thornton , Cheng, Paul , To, Christina , Oluwole, Olalekan O. , Sureda, Anna , van Meerten, Tom , Wannesson, Luciano , Leslie, Lori , Kersten, Marie José , Jacobson, Caron A , Pagel, John M , Wulf, Gerald , Johnston, Patrick , Rapoport, Aaron P , Du, Linqiu , Vardhanabhuti, Saran , Filosto, Simone , Shah, Jina , Snider, Julia T , Cheng, Paul , To, Christina , Oluwole, Olalekan O , Sureda, Anna , Farooq, Umar , Perales, Miguel-Angel , Miklos, David B , Westin, Jason R , Dickinson, Michael , Ghobadi, Armin , Locke, Frederick L

Clinical Cancer Research | March 31, 2023 | Volume: 29 | Issue: 10 | Pages: 1894-1905

10.1158/1078-0432.ccr-22-3136 | PMID 36999993 Get It

Abstract Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7. Patients and Methods: Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2–3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs). Results: Fifty-one and 58 patients aged ≥65 years were randomized to axi-cel and SOC, respectively. Median EFS was greater with axi-cel versus SOC (21.5 vs. 2.5 months; median follow-up: 24.3 months; HR, 0.276; descriptive P < 0.0001). Objective response rate was higher with axi-cel versus SOC (88% vs. 52%; OR, 8.81; descriptive P < 0.0001; complete response rate: 75% vs. 33%). Grade ≥3 adverse events occurred in 94% of axi-cel and 82% of SOC patients. No grade 5 cytokine release syndrome or neurologic events occurred. In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global Health, Physical Functioning, and EQ-5D-5L visual analog scale (descriptive P < 0.05). CAR T-cell expansion and baseline serum inflammatory profile were comparable in patients ≥65 and <65 years. Conclusions: Axi-cel is an effective second-line curative-intent therapy with a manageable safety profile and improved PROs for patients ≥65 years with R/R LBCL.
Is dorsal root entry zone lesioning effective and safe for managing continuous versus paroxysmal pains post–brachial plexus avulsion?
Pennington, Zach , Ochuba, Arinze , Khalifeh, Jawad M. , Al‐Mistarehi, Abdel‐Hameed , Belzberg, Allan J., Pennington, Zach , Lubelski, Daniel

Journal of Neurosurgery: Spine | March 31, 2023 | Volume: 39 | Issue: 1 | Pages: 101-112

10.3171/2023.2.spine221252 | PMID 37021771 Get It

OBJECTIVE Patients with brachial plexus avulsion (BPA) experience chronic deafferentation pain characterized by two patterns: continuous background pain and electrical shooting paroxysmal attacks. The authors’ aim was to report the effectiveness and safety of dorsal root entry zone (DREZ) lesioning in relieving the two forms of pain over short and long periods. METHODS All patients who underwent DREZ lesioning performed by the senior author for medically refractory BPA-related pain between July 1, 2016, and June 30, 2020, in Johns Hopkins Hospital were followed up. The intensity levels for continuous and paroxysmal pains were evaluated using the numeric rating scale (NRS) preoperatively and at 4 time points postsurgery, including the day of discharge, with a mean hospital stay of 5.6 ± 1.8 days; first postoperative clinic visit (33.0 ± 15.7 days); short-term follow-up (4.0 ± 1.4 months); and long-term follow-up (3.1 ± 1.3 years). The percent of pain relief according to the NRS was categorized into excellent (≥ 75%), fair (25%–74%), and poor (< 25%). RESULTS A total of 19 patients were included, with 4 (21.1%) lost to long-term follow-up. The mean age was 52.7 ± 13.6 years; 16 (84.2%) were men, and 10 (52.6%) had left-sided injuries. A motor vehicle accident was the most common etiology of BPA (n = 16, 84.2%). Preoperatively, all patients had motor deficits, and 8 (42.1%) experienced somatosensory deficits. The greatest pain relief was observed at the first postoperative and short-term follow-up visits, with the lowest proportions of patients having continuous pain (26.3% and 23.5%, respectively) and paroxysmal pain (5.3% and 5.9%, respectively). Also, the highest reductions in mean NRS scores were observed for first postoperative and short-term follow-up visits (continuous 1.1 ± 2.1 and 1.1 ± 2.3; paroxysms 0.4 ± 1.4 and 0.5 ± 1.7, respectively) compared to the preoperative symptomatology (continuous 6.7 ± 3.0; paroxysms 7.9 ± 4.3) (p < 0.001). Most patients had excellent relief of continuous pain (82.4% and 81.3%) and of paroxysms (90.9% and 90.0%) at the first postoperative visit and short-term follow-up visit, respectively. The pain relief benefits had diminished by 3 years after surgery but remained significantly better than in the preoperative assessment. At the last evaluation, the proportion of patients achieving excellent relief of paroxysmal pain (66.7%) was double that for continuous pain (35.7%) (p < 0.001). New sensory phenomena were observed among 10 patients (52.6%), and 1 patient developed a motor deficit. CONCLUSIONS DREZ lesioning is an effective and safe option for relieving BPA-associated pain, with good long-term outcomes and better benefits for paroxysmal pain than for the continuous pain component.
Do comorbid self-reported depression and anxiety influence outcomes following surgery for cervical spondylotic myelopathy?
Chan, Andrew K. , Shaffrey, Christopher I. , Park, Christine , Gottfried, Oren N., Than, Khoi D. , Bisson, Erica F. , Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Park, Paul , Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Michalopoulos, Giorgos D. , Sherrod, Brandon A. , Agarwal, Nitin , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V. , Michalopoulos, Giorgos

Journal of Neurosurgery: Spine | March 31, 2023 | Volume: 39 | Issue: 1 | Pages: 11-27

10.3171/2023.2.spine22685 | PMID 37021762 Get It

OBJECTIVE Depression and anxiety are associated with inferior outcomes following spine surgery. In this study, the authors examined whether patients with cervical spondylotic myelopathy (CSM) who have both self-reported depression (SRD) and self-reported anxiety (SRA) have worse postoperative patient-reported outcomes (PROs) compared with patients who have only one or none of these comorbidities. METHODS This study is a retrospective analysis of prospectively collected data from the Quality Outcomes Database CSM cohort. Comparisons were made among patients who reported the following: 1) either SRD or SRA, 2) both SRD and SRA, or 3) neither comorbidity at baseline. PROs at 3, 12, and 24 months (scores for the visual analog scale [VAS] for neck pain and arm pain, Neck Disability Index [NDI], modified Japanese Orthopaedic Association [mJOA] scale, EQ-5D, EuroQol VAS [EQ-VAS], and North American Spine Society [NASS] patient satisfaction index) and achievement of respective PRO minimal clinically important differences (MCIDs) were compared. RESULTS Of the 1141 included patients, 199 (17.4%) had either SRD or SRA alone, 132 (11.6%) had both SRD and SRA, and 810 (71.0%) had neither. Preoperatively, patients with either SRD or SRA alone had worse scores for VAS neck pain (5.6 ± 3.1 vs 5.1 ± 3.3, p = 0.03), NDI (41.0 ± 19.3 vs 36.8 ± 20.8, p = 0.007), EQ-VAS (57.0 ± 21.0 vs 60.7 ± 21.7, p = 0.03), and EQ-5D (0.53 ± 0.23 vs 0.58 ± 0.21, p = 0.008) than patients without such disorders. Postoperatively, in multivariable adjusted analyses, baseline SRD or SRA alone was associated with inferior improvement in the VAS neck pain score and a lower rate of achieving the MCID for VAS neck pain score at 3 and 12 months, but not at 24 months. At 24 months, patients with SRD or SRA alone experienced less change in EQ-5D scores and were less likely to meet the MCID for EQ-5D than patients without SRD or SRA. Furthermore, patient self-reporting of both psychological comorbidities did not impact PROs at all measured time points compared with self-reporting of only one psychological comorbidity alone. Each cohort (SRD or SRA alone, both SRD and SRA, and neither SRD nor SRA) experienced significant improvements in mean PROs at all measured time points compared with baseline (p < 0.05). CONCLUSIONS Approximately 12% of patients who underwent surgery for CSM presented with both SRD and SRA, and 29% presented with at least one symptom. The presence of either SRD or SRA was independently associated with inferior scores for 3- and 12-month neck pain following surgery, but this difference was not significant at 24 months. However, at long-term follow-up, patients with SRD or SRA experienced lower quality of life than patients without SRD or SRA. The comorbid presence of both depression and anxiety was not associated with worse patient outcomes than either diagnosis alone.
Top Ten Tips Palliative Care Clinicians Should Know About Delivering Specialty-Aligned Palliative Care
Leiter, Richard E. , Bischoff, Kara , Carey, Elise C. , Gelfand, Samantha L. , Iyer, Anand , Jain, Nelia , Kramer, Neha M. , Lally, Kate , Landzberg, Michael J., Lever, Natasha, Newport, Kristina , O’Donnell, Arden , Sciacca, Kate, Snaman, Jennifer M. , Tulsky, James A. , Rosa, William E. , Bischoff, Kara E , Iyer, Anand S , Tulsky, James A , Rosa, William E , Patel, Arpan , Lakin, Joshua R.

Journal of Palliative Medicine | March 31, 2023 | Volume: 26 | Issue: 10 | Pages: 1401-1407

10.1089/jpm.2023.0116 | PMID 37001173 Get It

Use of Artificial Intelligence for Digital Breast Tomosynthesis Screening: A Preliminary Real-world Experience
Letter, Haley , Peratikos, Meridith, Toledano, Alicia Y. , Hoffmeister, Jeffrey W. , Nishikawa, Robert M. , Shisler, Julie , Maimone, Santo , Villegas, Hector Diaz de, Maimone, Santo , Conant, Emily F.

Journal of Breast Imaging | March 31, 2023 | Volume: 5 | Issue: 3 | Pages: 258-266

10.1093/jbi/wbad015 | PMID 38416890 Get It

Abstract Objective The purpose of this study is to assess the “real-world” impact of an artificial intelligence (AI) tool designed to detect breast cancer in digital breast tomosynthesis (DBT) screening exams following 12 months of utilization in a subspecialized academic breast center. Methods Following IRB approval, mammography audit reports, as specified in the BI-RADS atlas, were retrospectively generated for five radiologists reading at three locations during a 12-month time frame. One location had the AI tool (iCAD ProFound AI v2.0), and the other two locations did not. The co-primary endpoints were cancer detection rate (CDR) and abnormal interpretation rate (AIR). Secondary endpoints included positive predictive values (PPVs) for cancer among screenings with abnormal interpretations (PPV1) and for biopsies performed (PPV3). Odds ratios (OR) with two-sided 95% confidence intervals (CIs) summarized the impact of AI across radiologists using generalized estimating equations. Results Nonsignificant differences were observed in CDR, AIR, and PPVs. The CDR was 7.3 with AI and 5.9 without AI (OR 1.3, 95% CI: 0.9–1.7). The AIR was 11.7% with AI and 11.8% without AI (OR 1.0, 95% CI: 0.8–1.3). The PPV1 was 6.2% with AI and 5.0% without AI (OR 1.3, 95% CI: 0.97–1.7). The PPV3 was 33.3% with AI and 32.0% without AI (OR 1.1, 95% CI: 0.8–1.5). Conclusion Although we are unable to show statistically significant changes in CDR and AIR outcomes in the two groups, the results are consistent with prior reader studies. There is a nonsignificant trend toward improvement in CDR with AI, without significant increases in AIR.
Creation and preclinical evaluation of a novel mussel-inspired, biomimetic, bioactive bone graft scaffold: direct comparison with Infuse bone graft using a rat model of spinal fusion
Cottrill, Ethan , Pennington, Zach , Perdomo‐Pantoja, Alexander , Rajkovic, Christian , Lin, Jessica, Mageau, Ashlie, Stewart, Veronica , Sciubba, Daniel M. , Elisseeff, Jennifer H. , Pennington, Zach , Wolf, Matthew T. , Dirckx, Naomi , Ehresman, Jeff , Lin, Jessica, Maestas, David R. , Lambrechts, Dennis , Theodore, Nicholas , Witham, Timothy F.

Journal of Neurosurgery: Spine | March 31, 2023 | Volume: 39 | Issue: 1 | Pages: 113-121

10.3171/2023.2.spine22936 | PMID 37021767 Get It

OBJECTIVE Infuse bone graft is a widely used osteoinductive adjuvant; however, the simple collagen sponge scaffold used in the implant has minimal inherent osteoinductive properties and poorly controls the delivery of the adsorbed recombinant human bone morphogenetic protein–2 (rhBMP-2). In this study, the authors sought to create a novel bone graft substitute material that overcomes the limitations of Infuse and compare the ability of this material with that of Infuse to facilitate union following spine surgery in a clinically translatable rat model of spinal fusion. METHODS The authors created a polydopamine (PDA)–infused, porous, homogeneously dispersed solid mixture of extracellular matrix and calcium phosphates (BioMim-PDA) and then compared the efficacy of this material directly with Infuse in the setting of different concentrations of rhBMP-2 using a rat model of spinal fusion. Sixty male Sprague Dawley rats were randomly assigned to each of six equal groups: 1) collagen + 0.2 µg rhBMP-2/side, 2) BioMim-PDA + 0.2 µg rhBMP-2/side, 3) collagen + 2.0 µg rhBMP-2/side, 4) BioMim-PDA + 2.0 μg rhBMP-2/side, 5) collagen + 20 µg rhBMP-2/side, and 6) BioMim-PDA + 20 µg rhBMP-2/side. All animals underwent posterolateral intertransverse process fusion at L4–5 using the assigned bone graft. Animals were euthanized 8 weeks postoperatively, and their lumbar spines were analyzed via microcomputed tomography (µCT) and histology. Spinal fusion was defined as continuous bridging bone bilaterally across the fusion site evaluated via µCT. RESULTS The fusion rate was 100% in all groups except group 1 (70%) and group 4 (90%). Use of BioMim-PDA with 0.2 µg rhBMP-2 led to significantly greater results for bone volume (BV), percentage BV, and trabecular number, as well as significantly smaller trabecular separation, compared with the use of the collagen sponge with 2.0 µg rhBMP-2. The same results were observed when the use of BioMim-PDA with 2.0 µg rhBMP-2 was compared with the use of the collagen sponge with 20 µg rhBMP-2. CONCLUSIONS Implantation of rhBMP-2–adsorbed BioMim-PDA scaffolds resulted in BV and bone quality superior to that afforded by treatment with rhBMP-2 concentrations 10-fold higher implanted on a conventional collagen sponge. Using BioMim-PDA (vs a collagen sponge) for rhBMP-2 delivery could significantly lower the amount of rhBMP-2 required for successful bone grafting clinically, improving device safety and decreasing costs.
Excessive Dynamic Airway Collapse Severity Scoring System
Lee‐Mateus, Alejandra Yu , Hernandez‐Rojas, Daniel , Pulipaka, Sai Priyanka , Garcia‐Saucedo, Juan C. , Majid, Adnan , Fernández-Bussy, Sebastián , Yu Lee-Mateus, Alejandra , Abia‐Trujillo, David , Saifi, Omran

Journal of Bronchology & Interventional Pulmonology | March 31, 2023 | Volume: 30 | Issue: 3 | Pages: 200-206

10.1097/lbr.0000000000000918 | PMID 36999946 Get It

Background: Severe excessive dynamic airway collapse (EDAC) is defined as airway narrowing due to posterior wall protrusion into the airway lumen, >90%. We aimed to establish an overall severity score to assess severe EDAC and the need for subsequent intervention. Methods: A retrospective study of patients who underwent dynamic bronchoscopy for evaluation of expiratory central airway collapse between January 2019 and July 2021. A numerical value was given to each tracheobronchial segmental collapse: 0 points (<70%), 1 point (70% to 79%), 2 points (80% to 89%), and 3 points (>90%) to be added for an overall EDAC severity score per patient. We compared the score among patients who underwent stent trials (severe EDAC) and those who did not. Based on the receiver operating characteristics curve, a cutoff total score to predict severe EDAC was calculated. Results: One hundred fifty-eight patients were included. Patients were divided into severe (n = 60) and nonsevere (n = 98) EDAC. A cutoff of 9 as the total score had a sensitivity of 94% and a specificity of 74% to predict severe EDAC, based on an area under the curve 0.888 (95% CI: 0.84, 0.93; P < 0.001). Conclusion: Our EDAC Severity Scoring System was able to discern between severe and nonsevere EDAC by an overall score cutoff of 9, with high sensitivity and specificity for predicting severe disease and the need for further intervention, in our institution.
A Between-Sex Comparison of the Genomic Architecture of Asthma
Zein, Joe , Bazeley, Peter , Meyers, Deborah A. , Bleecker, Eugene R. , Gaston, Benjamin , Ortega, Victor E. , Ortega, Victor, Hu, Bo , Attaway, Amy

American Journal of Respiratory Cell and Molecular Biology | March 31, 2023 | Volume: 68 | Issue: 4 | Pages: 456-458

10.1165/rcmb.2022-0430le | PMID 37000440 Get It

QIM23-138: Using the Electronic Health Record (EHR) to Capture Structured Oncology Data in Real-Time at the Point-of-Care: A Mayo Clinic Comprehensive Cancer Center (MCCCC) Pilot Study
Tevaarwerk, Amye J., Harlos, Elizabeth S., VanBebber, Heather L., Misel, Eli J., Nelson, Sacha A., Stockham, Abigail L. , Haddad, Tufia C. , Mandrekar, Sumithra J. , Maurer, Matthew J. , Vanbebber, Heather, Holton, Sara J., Alberts, Steven R. , McWilliams, Robert R.

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: QIM23-138

10.6004/jnccn.2022.7188 Get It